Top
image credit: Unsplash

Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering – Mar 12, 2021

March 12, 2021

Via: BioSpace

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Prometheus. The shares are expected to begin trading on the Nasdaq Global Select Market on March 12, 2021 under the ticker symbol “RXDX”.

Read More on BioSpace